Century Therapeutics, Inc.
IPSCNasdaqCIK 1850119HealthcareFiscal year ends Dec 31
Reports and events: 109 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-04-0821:03 ET | SC 13D/A | Ownership report, active investor, amended | 0000919574-24-002417 |
| 2024-03-1407:45 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-24-034239 |
| 2024-03-1407:30 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001558370-24-003165 |
| 2024-01-1917:03 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-24-005271 |
| 2023-12-1110:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-124911 |
| 2023-12-0607:46 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-123816 |
| 2023-11-1408:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-23-117704 |
| 2023-11-0907:56 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-23-116008 |
| 2023-11-0907:00 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001558370-23-018408 |
| 2023-10-0308:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-106149 |
| 2023-08-0907:40 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-23-089091 |
| 2023-08-0907:30 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001558370-23-014082 |
| 2023-06-2916:05 ET | 8-K | 5.07 Shareholder vote results | 0001104659-23-076308 |
| 2023-05-1107:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-058762 |
| 2023-05-1107:30 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001558370-23-009262 |
| 2023-05-0516:46 ET | 8-K/A | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-23-056605 |
| 2023-05-0516:40 ET | 8-K | 1.02 Termination of a material agreement | 0001104659-23-056599 |
| 2023-04-2816:05 ET | DEF 14A | Proxy statementPeriod 2023-06-27 | 0001104659-23-052908 |
| 2023-04-1716:14 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-23-046197 |
| 2023-03-2007:30 ET | 8-K | 7.01 Regulation FD disclosure | 0001104659-23-034217 |
| 2023-03-1607:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-033066 |
| 2023-03-1607:30 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001558370-23-003962 |
| 2023-03-1307:30 ET | 8-K | 7.01 Regulation FD disclosure | 0001104659-23-031507 |
| 2023-01-0907:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-23-002039 |
| 2022-11-3007:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-22-123015 |
| 2022-11-1017:17 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-22-117265 |
| 2022-11-1007:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-116808 |
| 2022-11-1007:30 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001558370-22-017287 |
| 2022-10-1114:09 ET | SC 13D/A | Ownership report, active investor, amended | 0000919574-22-005902 |
| 2022-10-0307:09 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-22-104899 |
| 2022-09-0807:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-22-098391 |
| 2022-08-2507:46 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-094231 |
| 2022-08-1108:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-089028 |
| 2022-08-1107:31 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001558370-22-013181 |
| 2022-07-0116:31 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-22-076872 |
| 2022-06-1316:19 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-22-070540 |
| 2022-06-1016:17 ET | 8-K | 5.07 Shareholder vote results | 0001104659-22-070137 |
| 2022-05-1607:31 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001558370-22-008860 |
| 2022-05-1607:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-060841 |
| 2022-05-1009:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-058001 |
| 2022-04-2116:05 ET | DEF 14A | Proxy statementPeriod 2022-06-09 | 0001104659-22-048376 |
| 2022-04-1309:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-22-045299 |
| 2022-03-1717:01 ET | 10-K | Annual reportPeriod 2021-12-31 | 0001558370-22-003867 |
| 2022-03-1708:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-22-034767 |
| 2022-01-1308:30 ET | 8-K | 1.01 Entry into a material agreement | 0001104659-22-003803 |
| 2022-01-1113:20 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-22-003063 |
| 2022-01-1007:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-22-002486 |
| 2021-12-1607:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-21-150260 |
| 2021-11-1808:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-21-140909 |
| 2021-11-1008:30 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001558370-21-015400 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 3, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.